- Home
- ARMP vs NMS Comparison
ARMP vs NMS Comparison
Compare ARMP & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- NMS
- Stock Information
- Founded
- ARMP N/A
- NMS 1993
- Country
- ARMP United States
- NMS United States
- Employees
- ARMP N/A
- NMS N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- NMS Finance Companies
- Sector
- ARMP Health Care
- NMS Finance
- Exchange
- ARMP Nasdaq
- NMS Nasdaq
- Market Cap
- ARMP 80.0M
- NMS 76.6M
- IPO Year
- ARMP N/A
- NMS N/A
- Fundamental
- Price
- ARMP $1.98
- NMS $12.77
- Analyst Decision
- ARMP Strong Buy
- NMS
- Analyst Count
- ARMP 1
- NMS 0
- Target Price
- ARMP $7.00
- NMS N/A
- AVG Volume (30 Days)
- ARMP 9.2K
- NMS 12.0K
- Earning Date
- ARMP 11-13-2024
- NMS 01-01-0001
- Dividend Yield
- ARMP N/A
- NMS 4.11%
- EPS Growth
- ARMP N/A
- NMS N/A
- EPS
- ARMP N/A
- NMS N/A
- Revenue
- ARMP $5,467,000.00
- NMS N/A
- Revenue This Year
- ARMP N/A
- NMS N/A
- Revenue Next Year
- ARMP $83.33
- NMS N/A
- P/E Ratio
- ARMP N/A
- NMS N/A
- Revenue Growth
- ARMP 34.92
- NMS N/A
- 52 Week Low
- ARMP $1.97
- NMS $9.21
- 52 Week High
- ARMP $4.48
- NMS $12.18
- Technical
- Relative Strength Index (RSI)
- ARMP 38.26
- NMS 25.93
- Support Level
- ARMP $1.97
- NMS $13.05
- Resistance Level
- ARMP $2.30
- NMS $13.10
- Average True Range (ATR)
- ARMP 0.11
- NMS 0.12
- MACD
- ARMP -0.02
- NMS -0.05
- Stochastic Oscillator
- ARMP 7.50
- NMS 0.00
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.